BioCentury | Feb 28, 2020
Distillery Therapeutics

An antisense oligo inhibitor of miR-132 for heart failure

DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure The miR-132 inhibitor CDR132L could treat heart failure. In pigs with post-myocardial infarction heart failure, CDR132L improved cardiac function, prevented end-systolic volume enlargement and reduced histologic evidence of interstitial...
BC Extra | Feb 1, 2020
Preclinical News

Cardior eyes heart failure cure with miRNA inhibitor

Cardior unveiled data on Friday that demonstrates its first clinical candidate goes beyond treating the cardiovascular symptoms of heart failure to reversing established disease in animal models. Cardior Pharmaceuticals GmbH, which spun out of Hannover...
BC Extra | Nov 13, 2019
Clinical News

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it...
BioCentury | Sep 14, 2019
Finance

Mark Schoenebaum: Setting the gold standard

In a business dominated by numbers, calculations, dollars and cents, Mark Schoenebaum understood that humanity, kindness and humility are paramount. This understanding gave him a boost that allowed him to reinvent what it means to...
BC Extra | Aug 2, 2019
Company News

Management tracks: Third Rock-backed Thrive names new CEO; plus PhRMA, Adverum and more

Thrive Earlier Detection Corp. (Cambridge, Mass.) said David Daly will succeed Steve Kafka as CEO, effective Aug. 19. Daly was chief commercial officer of the Foundation Medicine Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Kafka is...
BC Week In Review | Jul 13, 2018
Company News

Regulus reducing headcount by 60%

Regulus Therapeutics Inc. (NASDAQ:RGLS) reduced its headcount by an additional 60% and paused recruitment efforts for its RG-012 clinical program in Alport syndrome to save cash. In May 2017, the company reduced its headcount by...
BC Extra | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over...
BC Innovations | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
BC Week In Review | Apr 13, 2018
Company News

AZ gets NASH candidate from Ionis

AstraZeneca plc (LSE:AZN; NYSE:AZN) exercised an option to obtain worldwide rights to non-alcoholic steatohepatitis (NASH) antisense candidate IONIS-AZ6-2.5-L Rx (AZD2693) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS). Ionis will receive $30 million from AstraZeneca and is eligible...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
Items per page:
1 - 10 of 185
BioCentury | Feb 28, 2020
Distillery Therapeutics

An antisense oligo inhibitor of miR-132 for heart failure

DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure The miR-132 inhibitor CDR132L could treat heart failure. In pigs with post-myocardial infarction heart failure, CDR132L improved cardiac function, prevented end-systolic volume enlargement and reduced histologic evidence of interstitial...
BC Extra | Feb 1, 2020
Preclinical News

Cardior eyes heart failure cure with miRNA inhibitor

Cardior unveiled data on Friday that demonstrates its first clinical candidate goes beyond treating the cardiovascular symptoms of heart failure to reversing established disease in animal models. Cardior Pharmaceuticals GmbH, which spun out of Hannover...
BC Extra | Nov 13, 2019
Clinical News

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it...
BioCentury | Sep 14, 2019
Finance

Mark Schoenebaum: Setting the gold standard

In a business dominated by numbers, calculations, dollars and cents, Mark Schoenebaum understood that humanity, kindness and humility are paramount. This understanding gave him a boost that allowed him to reinvent what it means to...
BC Extra | Aug 2, 2019
Company News

Management tracks: Third Rock-backed Thrive names new CEO; plus PhRMA, Adverum and more

Thrive Earlier Detection Corp. (Cambridge, Mass.) said David Daly will succeed Steve Kafka as CEO, effective Aug. 19. Daly was chief commercial officer of the Foundation Medicine Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). Kafka is...
BC Week In Review | Jul 13, 2018
Company News

Regulus reducing headcount by 60%

Regulus Therapeutics Inc. (NASDAQ:RGLS) reduced its headcount by an additional 60% and paused recruitment efforts for its RG-012 clinical program in Alport syndrome to save cash. In May 2017, the company reduced its headcount by...
BC Extra | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over...
BC Innovations | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
BC Week In Review | Apr 13, 2018
Company News

AZ gets NASH candidate from Ionis

AstraZeneca plc (LSE:AZN; NYSE:AZN) exercised an option to obtain worldwide rights to non-alcoholic steatohepatitis (NASH) antisense candidate IONIS-AZ6-2.5-L Rx (AZD2693) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS). Ionis will receive $30 million from AstraZeneca and is eligible...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
Items per page:
1 - 10 of 185